MMRF CoMMpass Study

For Clinicians

For Patients
For Clinicians
Current Study Sites
In The News

The MMRF CoMMpass study is a prospective observational study in patients with symptomatic multiple myeloma who have not yet initiated therapy for their disease. The CoMMpass study will give clinicians access to data and insights that will help in the discovery of next generation of multiple myeloma treatments targeted towards patients with specific markers.

What is expected of patients during the MMRF CoMMpass study?

Patients will primarily receive their usual care throughout the study. In addition to the usual tests and treatments, we also ask doctors to collect a small amount of additional blood and bone marrow aspirate, when these procedures are performed at several times throughout the study.

What treatments will multiple myeloma patients receive while enrolled in the MMRF CoMMpass study?

The selection of drug treatment, dose and regimen is at the investigator’s discretion; however, the initial regimen must include an IMiD® and/or proteasome inhibitor.

When will the MMRF CoMMpass study end?

The study will end when all patients have received at least 5 years of follow-up.

Eligibility standards

We are looking for patients who fulfill the following entry criteria:

Inclusion Criteria

  • Male/female 18 years of age
  • Symptomatic multiple myeloma with measurable disease that includes at least one of the following:
    • Serum M protein 1 g/dL Urine M protein 200 mg/24 hrs Involved free light chain level 10 mg/dL and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • Candidate for systemic therapy that includes an IMiD® (e.g. lenalidomide, pomalidomide, or thalidomide) and/or a proteasome inhibitor as part of the initial regimen.
  • No more than 30 days from baseline bone marrow evaluation to initiation of therapy.
  • Be able to read, understand, and sign the Informed Consent document.

Exclusion Criteria

  • Patient is already receiving systemic therapy for MM (a single dose of bisphosphonates and up to 100 mg total dose of dexamethasone or equivalent corticosteroids are permitted prior to registration on study).
  • Patient had another malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix).
  • Patient is enrolled in a blinded clinical trial for the first-line treatment of multiple myeloma. Patients may be enrolled in subsequent clinical trials as long as continued access to data and tissue, as per this protocol, is not prohibited.

How do I find out more?

If you are a clinician interested in referring patients for participation in the MMRF CoMMpass study, or if you have questions regarding participation in the study please contact study coordinators at 203-652-0213 or email Beverly Harrison at

Back to top